Once-Daily Foscarnet As a Treatment Strategy for HHV-6 Reactivation after Allogeneic Stem Cell Transplantation

Key Points

• Foscarnet effectively reduces HHV-6 reactivation following allogeneic stem cell transplantation, improving patient outcomes.
• A significant metric is the observed decrease in reactivation rates among treated patients over time.
• The trial utilized an observational analysis across several centers focusing on treatment response rates.
• This new approach highlights the potential benefits of antiviral strategies following stem cell transplants, warranting further exploration.